Looking back: Daniel Callahan
By Michael Cook,
BioEdge
| 06. 13. 2015
Untitled Document
The dominant view of bioethics frames issues in terms of autonomy and individual rights. A retrospective in the Cambridge Quarterly of Heathcare Ethics, by Daniel Callahan, one of the grand old men of American bioethics, is a reminder of a broader and more communitarian view of the discipline.
Callahan is a restless thinker who did his undergraduate study at Yale and his PhD at Harvard. But the academic life did not suit him and he turned to journalism and for several years edited Commonweal, an influential Catholic journal. After splitting with the Church over abortion, in 1969 he co-founded The Hastings Center, a leading bioethics think tank.
Here are a few paragraphs:
I became known as an autonomy-basher, not because I objected to autonomy as an important human value but because I objected to an undercurrent trend that seemed to reduce ethics itself to nothing but individual free choice disconnected from an even more important question: what counts as a good or bad choice, a good or bad person, or a good or bad society? Those questions...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...